News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
GlaxoSmithKline (JOBS) to Pay Actelion Ltd. up to $3.3 Billion for Drug Rights
July 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - GlaxoSmithKline Ltd could pay Swiss company Actelion Ltd up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Layoff Tracker
Prothena Downsizes by 63% in Aftermath of AL Amyloidosis Failure
June 23, 2025
·
145 min read
·
BioSpace Editorial Staff
Business
Navigating Funding Freezes and AI Frontiers
June 20, 2025
·
1 min read
·
Lori Ellis
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
·
2 min read
·
Tristan Manalac
Podcast
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
June 18, 2025
·
1 min read
·
Heather McKenzie
